Profile data is unavailable for this security.
About the company
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
- Revenue in USD (TTM)8.00k
- Net income in USD-26.54m
- Incorporated2001
- Employees23.00
- LocationGenelux Corp2625 Townsgate Road, Suite 230WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 267-9889
- Fax+1 (302) 636-5454
- Websitehttps://genelux.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMV Pharmaceuticals Inc | 0.00 | -48.88m | 78.31m | 63.00 | -- | 0.3654 | -- | -- | -0.9662 | -0.9662 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -20.38 | -21.16 | -21.39 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 78.32m | 93.00 | -- | 2.98 | -- | 12.40 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.00m | 78.40m | 68.00 | -- | 0.8143 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Chimerix Inc | 144.00k | -84.70m | 78.43m | 72.00 | -- | 0.5041 | -- | 544.68 | -0.9507 | -0.9507 | 0.0016 | 1.74 | 0.0007 | -- | 1.86 | 2,000.00 | -40.37 | -30.45 | -44.33 | -34.09 | 10.42 | -- | -58,820.14 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -34.44m | 78.49m | 16.00 | -- | 24.19 | -- | -- | -0.934 | -0.934 | 0.00 | 0.0504 | 0.00 | -- | -- | 0.00 | -204.48 | -111.48 | -838.03 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Renovaro Inc | 0.00 | -88.12m | 79.21m | 11.00 | -- | 0.4698 | -- | -- | -1.08 | -1.08 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -60.56 | -27.81 | -68.21 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 80.69m | 66.00 | -- | -- | -- | 21.70 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 81.17m | 41.00 | -- | 0.7745 | -- | 83.64 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Genelux Corp | 8.00k | -26.54m | 81.85m | 23.00 | -- | 2.14 | -- | 10,231.13 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 82.37m | 12.00 | -- | 8.11 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Cidara Therapeutics Inc | 31.58m | -116.17m | 82.49m | 69.00 | -- | 0.409 | -- | 2.61 | -25.49 | -25.30 | 6.95 | 28.66 | 0.2617 | -- | 8.06 | 457,623.20 | -96.27 | -65.23 | -136.45 | -154.37 | 91.14 | -- | -367.91 | -100.61 | -- | -- | 0.0053 | -- | -0.8425 | -- | 31.72 | -- | 23.33 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 82.57m | 47.00 | -- | 2.58 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Medicinova Inc | 1.00m | -8.16m | 82.89m | 13.00 | -- | 1.44 | -- | 82.89 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 83.04m | 40.00 | -- | 0.934 | -- | 146.31 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Bioatla Inc | 0.00 | -104.56m | 84.10m | 65.00 | -- | 2.68 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Data as of Sep 19 2024. Currency figures normalised to Genelux Corp's reporting currency: US Dollar USD
15.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Woodward Diversified Capital LLCas of 30 Jun 2024 | 1.25m | 3.62% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 937.99k | 2.72% |
| Armistice Capital LLCas of 30 Jun 2024 | 900.00k | 2.61% |
| Highbridge Capital Management LLCas of 30 Jun 2024 | 631.31k | 1.83% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 392.44k | 1.14% |
| Millennium Management LLCas of 30 Jun 2024 | 300.22k | 0.87% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 282.15k | 0.82% |
| Geode Capital Management LLCas of 30 Jun 2024 | 226.31k | 0.66% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 180.25k | 0.52% |
| Provident Wealth Management LLCas of 30 Jun 2024 | 157.14k | 0.46% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
